Schizophrenia – Geographic Focus: China – China In-Depth – Schizophrenia
Managing the frequency and severity of psychotic episodes is the primary goal in the treatment of schizophrenia. Atypical antipsychotics are the preferred drug class, driven by physicians’ comfort and familiarity with the clinical profile of these drugs and the availability of generics. The availability of generic versions of key oral atypical antipsychotics (e.g., aripiprazole, olanzapine, paliperidone, lurasidone) is constraining the growth of emerging oral therapies with limited differentiation. Long-acting injectables (LAIs) are mainly reserved for schizophrenia patients who do not adhere to oral treatment. The schizophrenia pipeline includes agents targeting multiple underserved patient segments, including CIAS, negative symptoms, and inadequate responders. In this report, we explore how unmet needs, pricing, coverage, and regulatory reforms in China will impact the success of current and future players in this highly lucrative market.
Questions answered
- How large is China’s drug-treatable schizophrenia population, and how will drug-treatment rates change during the forecast period?
- Which are the most commercially relevant drugs in China’s schizophrenia market, and why?
- What are interviewed experts’ insights into current treatment options?
- What are the key unmet needs in the management of schizophrenia?
Product description
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific access and reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
NEW: China In-Depth reports include a custom drug modeler. This tool enables clients to input their own assumptions for a drug and forecast three scenarios that can be directly compared with Clarivate’s projections for drugs included in the patient-based market forecast. To access the tool, download the Market Forecast Dashboard file on the Insights Platform.
